Novo Nordisk has secured FDA accelerated approval for Wegovy, its GLP-1 drug, to treat metabolic dysfunction-associated steatohepatitis (MASH), a common variant of fatty liver disease. The new indication targets adults with non-cirrhotic MASH with moderate to advanced liver scarring. This development marks Wegovy as the first GLP-1 approved for MASH, addressing a condition estimated to affect approximately 22 million people in the United States. It enters a competitive landscape alongside Madrigal Pharmaceuticals’ Rezdiffra, which has seen strong sales since its own approval. Analysts predict some patient and physician preference shifts toward Wegovy for MASH tied to metabolic conditions, though distinct patient subgroups may continue to rely on existing therapies.